Who
Paul Glavine
Chief Growth Officer
Company insider
Files Form 4 as: Chief Growth Officer, Helus Pharma.
In numbers
- Trades disclosed
- 9
- Buys
- 4
- Sells
- 0
- Bought
- $9.4M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 31 Aug 2026
- Last trade
- 30 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 1 Oct 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Code A | —248,000 | filing |
| 8 Sep 2026filed 11 Sep 2026 | CybinBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.47 | filing |
| 8 Sep 2026filed 11 Sep 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.47 | filing |
| 8 Sep 2026filed 11 Sep 2026 | CybinBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.47 | filing |
| 8 Sep 2026filed 11 Sep 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.47 | filing |
| 3 Sep 2026filed 10 Sep 2026 | CybinBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $11.78 | filing |
| 3 Sep 2026filed 10 Sep 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $11.78 | filing |
| 31 Aug 2026filed 9 Sep 2026 | CybinBiotechnology | SEC FORM 4 Bought | $1.0M90,000 at $11.59 | filing |
| 31 Aug 2026filed 9 Sep 2026 | HELP Helus PharmaBiotechnology | SEC FORM 4 Bought | $1.0M90,000 at $11.59 | filing |
News
Cybin (NASDAQ:HELP) Stock Price Target Raised at Wells Fargo & CompanyHELP · dailypolitical.com · 22 Oct 2026Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026HELP · brantfordexpositor.ca · 21 Oct 2026Helus Pharma Appoints Dr. Suresh Durgam to Board of DirectorsHELP · recorder.ca · 15 Oct 2026
0 headlines in the last 90 days name Paul Glavine; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.